Compass Therapeutics Ownership | Who Owns Compass Therapeutics?

Overview Forecast RevenueFinancials Chart

Compass Therapeutics Ownership Summary

Compass Therapeutics is owned by 67.48% institutional investors, 12.04% insiders, and 20.48% retail investors. Orbimed advisors is the largest institutional shareholder, holding 16.37% of CMPX shares. Biotech Growth Ord is the top mutual fund, with 2.60% of its assets in Compass Therapeutics shares.

CMPX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Compass Therapeutics	67.48%	12.04%	20.48%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Orbimed advisors	22.36M	16.37%	$22.36M
Adage capital partners gp	11.13M	8.15%	$11.13M
Blackstone	7.69M	5.63%	$7.69M
Blackrock	6.61M	4.84%	$6.61M
Rock springs capital management lp	5.51M	4.04%	$5.51M
Janus henderson group	5.22M	3.82%	$5.76M
Bioimpact capital	5.01M	3.66%	$5.01M
Vanguard group	4.19M	3.07%	$4.19M
Fmr	4.13M	3.02%	$4.13M
Vivo capital	3.56M	2.60%	$3.56M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Blue owl capital lp	2.83M	0.79%	$2.83M
Bioimpact capital	5.01M	0.78%	$5.01M
Orbimed advisors	22.36M	0.44%	$22.36M
Vivo capital	3.56M	0.33%	$3.56M
Cm management	310.00K	0.28%	$310.00K
Caxton	43.47K	0.22%	$43.47K
Rock springs capital management lp	5.51M	0.17%	$5.51M
Monashee investment management	500.00K	0.06%	$500.00K
Blackstone	7.69M	0.03%	$7.69M
Dafna capital management	116.88K	0.03%	$116.88K

Top Buyers

Holder	Shares	% Assets	Change
Bioimpact capital	5.01M	0.78%	3.03M
Blackstone	7.69M	0.03%	1.50M
Blackrock	6.61M	0.00%	581.17K
Millennium management	433.75K	0.00%	239.99K
Geode capital management	2.29M	0.00%	215.35K

Top Sellers

Holder	Shares	% Assets	Change
Opaleye management	-	-	-3.17M
Cormorant asset management, lp	-	-	-2.03M
Janus henderson group	5.22M	0.00%	-1.28M
Fmr	4.13M	0.00%	-384.76K
Pennant investors, lp	-	-	-199.00K

New Positions

Holder	Shares	% Assets	Change	Value
Panagora asset management	68.27K	0.00%	68.27K	$68.27K
Gsa capital partners llp	65.92K	0.00%	65.92K	$66.00K
Corebridge financial	54.87K	0.00%	54.87K	$54.87K
Lpl financial	50.00K	-	50.00K	$50.00K
Mirae asset global etfs	45.56K	0.00%	45.56K	$45.56K

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-16.00
Point72 asia (singapore) pte.	-391.00
Hartford financial management	-1.00K
Metropolitan life insurance co/ny	-1.93K
Federated hermes	-3.59K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	79	-2.47%	92,186,861	-0.73%	67	1.46%	40	-14.89%	19	11.76%
Jun 30, 2024	81	3.85%	92,861,661	-1.80%	67	1.23%	47	74.07%	17	-51.43%
Mar 31, 2024	78	2.63%	94,562,990	9.81%	74	1.62%	27	-20.59%	35	40.00%
Dec 31, 2023	76	-	86,111,899	-4.02%	67	1.35%	34	-10.53%	25	31.58%
Sep 30, 2023	76	5.56%	89,720,729	-0.84%	70	1.38%	38	-13.64%	19	5.56%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Biotech Growth Ord	3.57M	2.60%	-
Vanguard Total Stock Mkt Idx Inv	2.61M	1.90%	421.00K
iShares Russell 2000 ETF	2.52M	1.83%	-5.66K
Vanguard Institutional Extnd Mkt Idx Tr	1.38M	1.00%	-
Fidelity Small Cap Index	1.02M	0.74%	-3.44K
iShares Russell 2000 Value ETF	939.39K	0.68%	-
Fidelity Extended Market Index	576.89K	0.42%	-51.76K
State St Russell Sm/Mid Cp® Indx NL Cl C	561.20K	0.41%	-21.00K
Janus Henderson Hrzn Biotec E2 USD	534.18K	0.39%	-1.42K
Vanguard Russell 2000 ETF	465.02K	0.34%	-2.89K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 10, 2023	Schuetz Thomas J.	CHIEF EXECUTIVE OFFICER	Buy	$33.70K
Feb 27, 2023	Schuetz Thomas J.	CHIEF EXECUTIVE OFFICER	Buy	$79.60K
Feb 15, 2023	Schuetz Thomas J.	CHIEF EXECUTIVE OFFICER	Buy	$77.20K
Jan 31, 2023	Schuetz Thomas J.	CHIEF EXECUTIVE OFFICER	Buy	$81.00K
Jan 24, 2023	Schuetz Thomas J.	CHIEF EXECUTIVE OFFICER	Buy	$83.80K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	-
2024 Q3	-	-
2024 Q1	-	-
2023 Q4	-	-
2023 Q2	-	-

CMPX Ownership FAQ

Who Owns Compass Therapeutics?

Compass Therapeutics shareholders are primarily institutional investors at 67.48%, followed by 12.04% insiders and 20.48% retail investors. The average institutional ownership in Compass Therapeutics's industry, Biotech Stocks , is 47.04%, which Compass Therapeutics exceeds.

Who owns the most shares of Compass Therapeutics?

Compass Therapeutics’s largest shareholders are Orbimed advisors (22.36M shares, 16.37%), Adage capital partners gp (11.13M shares, 8.15%), and Blackstone (7.69M shares, 5.63%). Together, they hold 30.15% of Compass Therapeutics’s total shares outstanding.

Does Blackrock own Compass Therapeutics?

Yes, BlackRock owns 4.84% of Compass Therapeutics, totaling 6.61M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 6.61M$. In the last quarter, BlackRock increased its holdings by 581.17K shares, a 9.63% change.

Who is Compass Therapeutics’s biggest shareholder by percentage of total assets invested?

Blue owl capital lp is Compass Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.79% of its assets in 2.83M Compass Therapeutics shares, valued at 2.83M$.

Who is the top mutual fund holder of Compass Therapeutics shares?

Biotech Growth Ord is the top mutual fund holder of Compass Therapeutics shares, with 2.60% of its total shares outstanding invested in 3.57M Compass Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools